Fate Therapeutics Q1 2024 GAAP EPS $(0.47), Inline, Sales $1.925M Beat $1.114M Estimate
Fate Therapeutics Q1 2024 GAAP EPS $(0.47), Inline, Sales $1.925M Beat $1.114M Estimate
Fate Therapeutics 2024年第一季度公认会计准则每股收益美元 (0.47)，内联，销售额19.25万美元超过11.14亿美元的预期
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This is a 147.37 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $1.925 million which beat the analyst consensus estimate of $1.114 million by 72.76 percent. This is a 96.74 percent decrease over sales of $58.980 million the same period last year.
Fate Therapeutics（纳斯达克股票代码：FATE）公布的季度亏损为每股0.47美元，符合分析师的共识预期。这比去年同期每股亏损0.19美元（0.19美元）下降了147.37％。该公司公布的季度销售额为19.25万美元，比分析师普遍预期的11.4万美元高出72.76％。这比去年同期的5,8980万美元的销售额下降了96.74％。